Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir Prophylaxis After allo-HSCT in Children With EBV-LPD and EBV-HLH
NCT07488728Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoint: Incidence of Clinically Significant CMV Infection (cs-CMVi) and EBV Infection (cs-EBVi) at 360 days. Started Oct 2025; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07488728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488728.